Jubbonti

Denosumab, the active ingredient in Jubbonti, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It is a bone resorption inhibitor indicated for osteoporosis in postmenopausal women and men at high risk of fracture, and for preventing skeletal‑related events in patients with bone metastases from solid tumors.

GNH USA supplies Jubbonti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Denosumab acts on the RANK/RANKL pathway to treat bone‑loss conditions and cancer‑related skeletal complications.

- Osteoporosis in postmenopausal women: reduces risk of vertebral, non‑vertebral and hip fractures. - Osteoporosis in men at high risk of fracture: decreases incidence of fractures. - Prevention of skeletal‑related events in patients with bone metastases from solid tumors: delays or reduces pathologic fractures, spinal cord compression and need for radiation or surgery.

Denosumab may be associated with a range of adverse reactions, which are categorised by frequency.

Common Side Effects: - Injection site pain or erythema. - Low blood calcium levels (hypocalcemia). - Musculoskeletal pain. - Skin rash or pruritus. - Upper respiratory tract infection.

Serious or Rare Side Effects: - Osteonecrosis of the jaw. - Atypical femur fracture. - Severe hypersensitivity reactions including anaphylaxis. - Severe hypocalcemia requiring medical intervention.

Before initiating therapy with Denosumab, several precautions should be considered. - Calcium and vitamin D status: assess and correct deficiencies before treatment. - Hypocalcemia monitoring: check serum calcium levels regularly during therapy. - Dental health: obtain a dental examination and complete any invasive procedures prior to starting. - Renal impairment: use with caution in patients with severe kidney disease. - Pregnancy and lactation: avoid use during pregnancy and breastfeeding until safety is established. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab can interact with other medicines, affecting calcium balance or immune function.

Major Interactions (Avoid): - Concurrent use with other potent bone resorption inhibitors (e.g., bisphosphonates) may increase risk of hypocalcemia. - Administration of live vaccines while receiving Denosumab may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Calcium supplements: may blunt the drug’s effect on bone turnover. - Vitamin D supplements: monitor for hypercalcemia. - Anticonvulsants that induce hepatic enzymes (e.g., phenytoin, carbamazepine): may lower vitamin D levels, increasing hypocalcemia risk. - Immunosuppressive agents: may augment infection risk. - Hormone replacement therapy: monitor bone turnover markers.